ARTHEx raises its funding round to USD 87 million for the development of its programme for myotonic dystrophy type 1, a rare genetic neuromuscular disease
ARTHEx Biotech, a clinical-stage biotechnology company focused on the development of RNA therapeutics targeting rare genetic neuromuscular disorders, has closed its funding round with the addition of a new investor, Bpifrance, and the participation of all existing shareholders, bringing the total amount to USD 87 million
The funds will be used to advance the global clinical development of its lead programme, ATX-01, for myotonic dystrophy type 1 (MD1), a rare genetic neuromuscular disease, including the Phase I/IIa ArthemiR™ trial.
ARTHEx is also expanding its portfolio of therapies in areas of high unmet medical need, including muscular, central nervous system, cardiac and pulmonary diseases.
A team led by David Pintos advised ARTHEx on this transaction.
